Aaron Chu
Family · Wichita, KSNPI 1467068742
Payments from drug & device makers
Across 89 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$736
- Pfizer$187
- AbbVie$156
- Novartis$151
- Lundbeck LLC$115
- Johnson & Johnson$51
- plus $322 from 12 others
What the payments were for
- Travel & lodging$29717%
- Food & beverage$1,33277%
- Education$905%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $736 |
| Pfizer | 21 | $187 |
| AbbVie | 8 | $156 |
| Novartis | 23 | $151 |
| Lundbeck LLC | 5 | $115 |
| Johnson & Johnson(2 entities) | 2 | $51 |
| Biogen | 3 | $46 |
| UCB, Inc. | 2 | $39 |
| TG Therapeutics, Inc. | 2 | $38 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Argenx US, Inc. | 1 | $33 |
| Bristol Myers Squibb | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Banner Life Sciences, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$346
- NURTEC ODT$121
How this compares
$1,719 in reported general payments places this provider in the 80th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 12 | $121,633 |
| EmflazaDeflazacort | 13 | $83,945 |
| Nurtec OdtRimegepant Sulfate | 55 | $63,793 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $37,925 |
| QuliptaAtogepant | 18 | $36,257 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $30,246 |
| Emgality PenGalcanezumab-Gnlm | 33 | $25,538 |
| RytaryCarbidopa/Levodopa | 20 | $21,056 |
| Lacosamide | 79 | $14,642 |
| UbrelvyUbrogepant | 14 | $14,185 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 336 | $14,087 |
| Dalfampridine ErDalfampridine | 19 | $10,760 |
| Levetiracetam | 236 | $9,305 |
| Gabapentin | 247 | $5,319 |
| Lamotrigine OdtLamotrigine | 20 | $4,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $187 | $63,79355 claims |
| AbbVieQulipta, Ubrelvy | $156 | $50,44232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.